Sunday, April 24, 2016

Possible patent challenge to Biogen's Tysabri

FiercePharma noted of Biogen's prospects:

India’s Swiss Pharma International has filed a petition for inter partes review of one of Tysabri’s patents--and another two petitions are on the way, Leerink Partners analyst Geoffrey Porges wrote in a note to clients on Monday. The move could potentially put sales of the drug, which tallied $1.89 billion in 2015, in jeopardy, he noted.



Post a Comment

<< Home